2018-11-15T20:44:58-06:00 2017-12-31 346565596 ERNST & YOUNG US LLP 18101 VON KARMAN AVENUE SUITE 1700 IRVINE CA 92612 990 2017-01-01 954772979 CALIFORNIA HEART CENTER FOUNDATION CALI 3102488327 8536 WILSHIRE BOULEVARD 3RD FLOOR BEVERLY HILLS CA 90211 JON KOBASHIGAWA MD PRESIDENT 3102488327 2018-11-15 1 KARA ADAMS P00023315 9497942300 192.231.86.241 2018-11-15 18:41:40 PS P 5D66495798EA847DC80F6602DD5A7F057B72F91F 441AA63A5AD28D5142E9094244EB82DFC70B9A9D 2017 2019-02-21 02:37:17Z JON KOBASHIGAWA MD 8536 WILSHIRE BOULEVARD 3RD FLOOR BEVERLY HILLS CA 90211 1689699 0 X WWW.CALHEART.ORG X 2000 CA PROMOTE & DEVELOP EDUCATIONAL & SCIENTIFIC RESEARCH TO ADVANCE THE FIELD OF CARDIOVASCULAR MEDICINE. 5 3 0 3 0 0 1531356 1466549 298766 223150 6 0 0 0 1830128 1689699 0 0 0 0 1422984 1388413 0 0 0 408790 338546 1831774 1726959 -1646 -37260 58893 24693 124806 127865 -65913 -103172 X THE MISSION OF THE CALIFORNIA HEART CENTER FOUNDATION IS TO ADVANCE THE FIELD OF CARDIOVASCULAR MEDICINE THROUGH CLINICAL RESEARCH INITIATIVES AND EDUCATIONAL INITIATIVES. 0 0 1508170 223150 THE MISSION OF THE CALIFORNIA HEART CENTER FOUNDATION IS TO ADVANCE THE FIELD OF CARDIOVASCULAR MEDICINE THROUGH CLINICAL RESEARCH INITIATIVES AND EDUCATIONAL INITIATIVES. OUR EFFORTS INCLUDE THE PURSUIT OF COLLABORATIVE RESEARCH PROJECTS WHICH PROMOTE A DEEPER UNDERSTANDING OF DISEASE PROGRESSION AND TEST THE EFFICACY OF NEW STRATEGIES FOR DIAGNOSIS AND TREATMENT. AREAS OF RESEARCH CURRENTLY BEING PURSUED INCLUDE NON-INVASIVE METHODS TO DETECT ORGAN REJECTION, NOVEL IMMUNOSUPPRESSIVE AGENTS, IMMUNE MONITORING STRATEGIES, LONG-TERM COMPLICATIONS SUCH AS CARDIAC ALLOGRAFT VASCULOPATHY, (CONTINUED ON SCHEDULE O)(CONTINUATION FROM FORM 990, PAGE 2)NOVEL METHODS FOR ORGAN PROCUREMENT AND PRESERVATION, NEW MECHANICAL CIRCULATORY SUPPORT DEVICES AND PULMONARY HYPERTENSION. THE ORGANIZATION ALSO SUPPORTS IMPORTANT SCIENTIFIC SYMPOSIA, WHICH ALLOW FOR THE EXCHANGE OF IDEAS AMONG LEADERS IN THE FIELD AND PROVIDE A FORUM FOR EXPERTS TO SHARE THEIR EXPERIENCE AND KNOWLEDGE WITH OTHER PRACTITIONERS. THE ORGANIZATION RESOURCES ARE ALSO LEVERAGED TO SUPPORT A SUMMER RESEARCH INTERNSHIP PROGRAM FOR UNDERGRADUATE STUDENTS WITH AN INTEREST IN MEDICINE AND/OR ACADEMIC RESEARCH. FOLLOWING IS A SUMMARY OF PROJECTS AND PROGRAMS IMPLEMENTED IN 2017: SCIENTIFIC FORUMS AND EDUCATIONAL ACTIVITIES:* "CUTTING EDGE OF TRANSPLANTATION (CEOT)", FEBRUARY 23TH - 25TH, 2017 (PHOENIX, ARIZONA): THIS MEETING, PLANNED BY THE AMERICAN SOCIETY OF TRANSPLANTATION, FEATURED SESSIONS FOCUSED ON HEART AND LUNG TRANSPLANTATION THAT WERE CHAIRED BY DR. JON KOBASHIGAWA AND SPONSORED BY THE CEDARS-SINAI HEART INSTITUTE. FOCUSED ON THE THEME OF "ONE TRANSPLANT FOR LIFE", THE HEART AND LUNG TRACKS EACH FEATURED 3 DEDICATED SESSIONS OVER THREE DAYS ON IMPROVING LONG-TERM OUTCOMES, THUS DECREASING THE LIKELIHOOD OF MULTIPLE TRANSPLANTS OVER A RECIPIENT'S LIFETIME, WITH LECTURES FOCUSING ON THE TREATMENT AND MANAGEMENT OF ANTIBODIES IN SOLID ORGAN TRANSPLANTATION. WITH DR. KOBASHIGAWA'S LEADERSHIP, THE HEART AND LUNG TRACKS FEATURED A FACULTY OF LEADING EXPERTS IN THE FIELD AND ATTRACTED THE HIGHEST ATTENDANCE FROM THE CARDIOTHORACIC COMMUNITY SINCE THE INCEPTION OF THE CEOT MEETING. * "A CONSENSUS CONFERENCE ON FRAILTY IN THORACIC TRANSPLANTATION", APRIL 29TH, 2017 (CHICAGO, IL): THIS CONFERENCE, PLANNED IN COORDINATION WITH THE 2017 AMERICAN TRANSPLANT CONGRESS, WAS DESIGNED TO PROVIDE A FORUM FOR AN IN-DEPTH DISCUSSION AMONG THE LEADING EXPERTS IN THE FIELD, INCLUDING CLINICIANS, SURGEONS AND ALLIED HEALTH. THE CONFERENCE SERVED AS A FIRST STEP IN DEVELOPING NEEDED GUIDELINES FOR THE ASSESSMENT AND TREATMENT OF FRAILTY IN PATIENTS BEING EVALUATED OR LISTED FOR HEART OR LUNG TRANSPLANTATION, TO IMPROVE OUTCOMES AND MINIMIZE POST-TRANSPLANT COMPLICATIONS. SUCH GUIDELINES CAN ALSO BE USED TO DEVELOP A PLATFORM FOR THE DEVELOPMENT OF MULTI-CENTER CLINICAL TRIALS TO FURTHER ASSESS THE EFFICACY OF THERAPIES. ATTENDED BY 47 PARTICIPANTS, REPRESENTING TRANSPLANT CENTERS ACROSS THE UNITED STATES AND CANADA, THE CONFERENCE GENERATED A ROBUST DISCUSSION AND HELPED TO IDENTIFY A PATHWAY TO THE DEVELOPMENT OF GUIDELINES. A PUBLICATION OF CONFERENCE RESULTS IS CURRENTLY PENDING.* "SUCCESS WITH FAILURE: AN ADVANCED HEART DISEASE SYMPOSIUM" (TORRANCE, CA): THIS 1-DAY SYMPOSIUM ON ADVANCED HEART DISEASE TOOK PLACE ON FRIDAY, JUNE 9TH, 2017. TWENTY-TWO FACULTY SPEAKERS COVERED TOPICS RELATED TO THE MANAGEMENT AND TREATMENT OF HEART FAILURE, INTERVENTIONAL PROCEDURES, AND MECHANICAL CIRCULATORY SUPPORT DEVICES AND TRANSPLANTATION AS TREATMENT OPTIONS FOR PATIENTS WITH ADVANCED HEART FAILURE. THE PROGRAM DREW 206 ATTENDEES CONSISTING OF PHYSICIANS, ALLIED HEALTH PROFESSIONALS, INCLUDING NURSE PRACTITIONERS, TRANSPLANT COORDINATORS, PHYSICIAN ASSISTANTS, RNS AND CASE MANAGERS FROM ACROSS SOUTHERN CALIFORNIA. THE PROGRAM WAS EXTREMELY WELL RECEIVED. * "ADVANCED HEART DISEASE VISITING PROFESSORSHIP - JACK COPELAND, MD", SEPTEMBER 11TH - 12TH, 2017: THIS PROFESSORSHIP WAS SPONSORED AND ORGANIZED BY DR. KOBASHIGAWA. THIS YEAR'S VISITING PROFESSOR WAS DR. JACK COPELAND, A PIONEER IN HEART TRANSPLANTATION AND MECHANICAL CIRCULATORY SUPPORT. HIS TWO-DAY VISIT FEATURED A GRAND ROUNDS LECTURE, A FELLOWS' CASE CONFERENCE, A LUNCH LECTURE FOR THE ADVANCED HEART DISEASE CLINICAL TEAMS. DR. COPELAND SHARED HIS UNIQUE PERSPECTIVE ON THE HISTORY AND FUTURE OF TRANSPLANTATION AS 2017 MARKS THE 50TH ANNIVERSARY OF THE FIRST HUMAN HEART TRANSPLANT.* "PRACTICUM IN MECHANICAL CIRCULATORY SUPPORT: AN EXPERT REVIEW" (LOS ANGELES, CA): THIS 2-DAY SYMPOSIUM ON MECHANICAL CIRCULATORY SUPPORT WAS DEVELOPED WITH THE CEDARS-SINAI OFFICE OF CONTINUING MEDICAL EDUCATION AND TOOK PLACE ON OCTOBER 27-28TH, 2017. IN ADDITION TO UTILIZING THE SIMULATION LABS AT CSMC, THE PROGRAM FEATURED 17 EXPERT GUEST FACULTY FROM ACROSS THE UNITED STATES PLUS 12 INTERNAL FACULTY. THE PROGRAM DREW 104 ATTENDEES INCLUDING PHYSICIANS, ALLIED HEALTH PROFESSIONALS, NURSE PRACTITIONERS, AND TRANSPLANT COORDINATORS AND PROVIDED LEARNERS WITH A COMPREHENSIVE OVERVIEW OF MECHANICAL CIRCULATORY SUPPORT.* "UPDATES ON DIAGNOSIS AND TREATMENT OPTIONS FOR CARDIOVASCULAR DISEASE IN THE OUTPATIENT SETTING" - 1-HOUR LUNCH LECTURE EDUCATIONAL SERIES:"THE BASICS OF STRESS TESTING" (MICHELLE KITTLESON, MD, PHD)THIS 1 -HOUR LECTURE WAS HELD ON FEBRUARY 21, 2017 IN THE KAWATA LIBRARY FOR THE CLINICAL STAFF OF CALIFORNIA HEART CENTER. ATTENDED BY 7 PARTICIPANTS, DR. KITTLESON PROVIDED AN OVERVIEW FOR THE INDICATIONS AND CONTRAINDICATIONS FOR STRESS TESTING, AND DISCUSSED THE VARIOUS TYPES AND THE CRITERIA FOR THE APPROPRIATE SELECTION OF STRESS TESTS."CARDIOMEMS" (BABAK AZARBAL, MD)THIS 1 -HOUR LECTURE WAS HELD ON SEPTEMBER 15, 2017 IN THE KAWATA LIBRARY FOR THE CLINICAL STAFF OF CALIFORNIA HEART CENTER. ATTENDED BY 16 PARTICIPANTS, DR. AZARBAL PROVIDED AN OVERVIEW FOR THE USE OF THE CARDIOMEMS DEVICE FOR THE MANAGEMENT OF PATIENTS WITH CONGESTIVE HEART FAILURE. "BASICS OF STRESS TESTING" (MICHELLE KITTLESON, MD, PHD)THIS 1 -HOUR LECTURE WAS HELD ON NOVEMBER 14TH, 2017 IN THE KAWATA LIBRARY FOR THE CLINICAL STAFF OF CALIFORNIA HEART CENTER. ATTENDED BY 12 PARTICIPANTS, DR. KITTLESON PROVIDED AN OVERVIEW FOR THE USE OF THE STRESS TESTING, INCLUDING INDICATIONS, CONTRAINDICATIONS, TYPES OF STRESS TESTS, AND INTERPRETATION.* HEART TRANSPLANT PRECEPTORSHIPS: THROUGHOUT THE YEAR, WE RECEIVE REQUESTS TO PROVIDE EXTENDED OBSERVATIONAL TRAINING OPPORTUNITIES TO PHYSICIANS AND ADVANCE PRACTICE NURSES FROM VARIOUS INSTITUTIONS WITH AN INTEREST IN THE MANAGEMENT OF HEART TRANSPLANT AND MECHANICAL ASSIST DEVICE PATIENTS. IN THE LAST YEAR, WE HOSTED THE FOLLOWING VISITORS:DR. SASHA VUKELIC (MONTEFIORE - ALBERT EINSTEIN SCHOOL OF MEDICINE)DR. BINOY CHATTUPARAMBIL (HEALTHCITY CAYMAN ISLANDS)DR. TAKUMA SATO (NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER, JAPAN)* SUMMER RESEARCH INTERNSHIPS: UNDER THE SUPERVISION AND MENTORSHIP OF DR. JON KOBASHIGAWA, SUMMER HEART TRANSPLANT RESEARCH INTERNSHIPS WERE OFFERED TO ELEVEN STUDENTS FOR THE SUMMER OF 2017. THESE INTERNSHIPS PROVIDE STUDENTS AT ALL LEVELS OF TRAINING AN OPPORTUNITY TO LEARN THE CLINICAL RESEARCH PROCESS, INCLUDING MEDICAL LITERATURE REVIEW, STUDY DESIGN, CHART REVIEW/DATA COLLECTION, DATA ANALYSIS, AND ABSTRACT DEVELOPMENT AND SUBMISSION. COMPLETED ABSTRACTS WERE SUBMITTED TO THE AMERICAN FEDERATION OF MEDICAL RESEARCH, A FORUM FOR JUNIOR INVESTIGATORS. THIS YEAR'S GROUP INCLUDES STUDENTS FROM:RICE UNIVERSITY LOYOLA MARYMOUNTUCLAAMHERST COLLEGEUC BERKELEYUSCCSUNCOLUMBIA UNIVERSITYUC DAVISOAKLAND UNIVERSITY BEAUMONT SCHOOL OF MEDICINE* "CURRENT TRENDS IN HEART TRANSPLANTATION: PATIENT EDUCATION SERIES"THIS PATIENT EDUCATION LECTURE BY DR. JON KOBASHIGAWA IS SCHEDULED TWICE A YEAR, COVERING CURRENT TRENDS IN HEART TRANSPLANTATION AND PROVIDING PATIENTS WITH AN OVERVIEW OF CUTTING EDGE INNOVATIONS IN THE FIELD OF HEART TRANSPLANTATION. FORUMS WERE HELD ON THURSDAY, JUNE 22ND, 2017 AND THURSDAY, DECEMBER 7TH, 2017 AT THE MEDICAL CENTER AND ATTENDED BY POST-TRANSPLANT PATIENTS AS WELL AS PATIENTS ON THE WAITING LIST FOR TRANSPLANTATION. CLINICAL RESEARCH:THIS SECTION IS FORMATTED BY TITLE; PRINCIPAL INVESTIGATOR (PI); STATUS; SPONSOR.DCM PRECISION MEDICINE STUDY; EVAN KRANSDORF, MD; ENROLLING; OHIO STATE UNIVERSITYTARGETING INFLAMMATION AND ALLOIMMUNITY IN HEART TRANSPLANT RECIPIENTS WITH TOCILIZUMAB; JIGNESH PATEL, MD, PHD; STUDY INITIATION; MASSACHUSETTS GENERAL HOSPITALTHE MEDICAL ARM OF MECHANICAL CIRCULATORY SUPPORT (MEDAMACS) STUDY; MICHELLE KITTLESON, MD, PHD; ENROLLMENT COMPLETE; UAB/NIHA RANDOMIZED TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF THE SHERPA PAK DEVICE FOR COLD STORAGE OF DONOR HEARTS IN TRANSPLANTATION: A PILOT STUDY; FARDAD ESMAILIAN, MD; STUDY START-UP; INTERNAL (PARAGONIX) 1508170 1 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 1 6 0 1 0 0 0 0 0 0 0 0 0 0 0 X 5 3 0 0 1 0 1 1 1 1 1 0 0 0 1 1 1 0 0 0 1 0 CA X DEBBIE BOTTEN 3104238473 15821 VENTURA BLVD STE 520 ENCINO CA 91436 JON KOBASHIGAWA MD PRESIDENT 2.00 0.00 X X 0 0 0 MICHELE HAMILTON MD CFO 2.00 0.00 X X 0 0 0 THOMAS D GORDON DIRECTOR 1.00 40.00 X 0 549717 76122 EDUARDO MARBAN MD DIRECTOR 1.00 60.00 X 0 2335876 202989 JAIME MORIGUCHI MD DIRECTOR 2.00 0.00 X 0 0 0 CHRISTINE SUMBI SECRETARY 40.00 0.00 X 0 177241 21242 0 3062834 300353 0 0 1 0 0 1466549 1466549 EDUCATIONAL PROGRAMS 611430 205581 205581 CULTURAL PROGRAMS 611710 17569 17569 223150 1689699 223150 0 0 179595 179595 1012008 1012008 46110 46110 59802 59802 90898 90898 36196 25337 10859 4471 4024 447 54462 54462 17487 17487 183119 173963 9156 2849 2849 MEALS AND ENTERTAINMENT 28383 9651 18732 DUES & SUBSCRIPTIONS 5572 5572 MOVING/STORAGE 2160 2160 CREDIT CARD FEES 1239 1239 2608 2608 1726959 1508170 218789 0 48209 23258 6886 486 107678 106729 3798 949 58893 24693 124806 127865 124806 127865 X -65913 -103172 -65913 -103172 58893 24693 X -37260 1 X 0 0 0 X 1357431 1514534 1784016 1531356 1466549 7653886 1357431 1514534 1784016 1531356 1466549 7653886 7653886 8138 5075 1031 6 0 14250 7668136 778007 0.99810 0.99650 X 70594 69645 949 37084 37084 0 949 0 1 0 0 0 0 0 0 0 THOMAS D GORDON DIRECTOR 0 278758 0 0 0 270959 0 64079 0 12043 0 625839 0 0 EDUARDO MARBAN MD DIRECTOR 0 1411760 0 368108 0 556008 0 168900 0 34089 0 2538865 0 0 CHRISTINE SUMBI SECRETARY 0 158201 0 18701 0 339 0 12571 0 8671 0 198483 0 0 PART I, LINE 3 PLEASE SEE SCHEDULE O NARRATIVE FOR PART VI, SECTION B LINE 15B. PART I, LINE 4B THE PLAN IS A SUPPLEMENTAL RETIREMENT ALLOWANCE THAT IS PAYABLE DIRECTLY TO THE PARTICIPANTS EACH QUARTER. THE BENEFIT FORMULA FOR THIS PLAN HAS ANNUAL CONTRIBUTIONS THAT ARE EITHER A PERCENTAGE OF SALARY, OR ARE DESIGNED TO FUND A PERCENTAGE OF THE ESTIMATED FINAL 5-YEAR AVERAGE SALARY. THE FOLLOWING DIRECTORS RECEIVED PAYMENTS DURING THE YEAR ENDED DECEMBER 31, 2017. THOMAS D. GORDON 72,530 EDUARDO MARBAN, MD 317,082 FORM 990, PART III, LINE 4A (CONTINUED) CELL-FREE DNA AND ANTIBODY-MEDIATED REJECTION IN A COHORT OF SENSITIZED HEART TRANSPLANT PATIENTS; JON KOBASHIGAWA, MD; ENROLLMENT COMPLETE; CSMC/CAREDX, INC. THE DE-NOVO USE OF ECULIZUMAB ALONGSIDE CONVENTIONAL THERAPY IN PRESENSITIZED PATIENTS RECEIVING CARDIAC TRANSPLANTATION: AN OPEN-LABEL, INVESTIGATOR-INITIATED PILOT TRIAL; JIGNESH PATEL, MD, PHD; ENROLLMENT COMPLETE; ALEXION PHARMACEUTICALS ADVANCED HEART DISEASE BIOBANK; ROBIN SHAW, MD; ENROLLING; CSMC ADVANCED HEART DISEASE REGISTRY; JON KOBASHIGAWA, MD; ENROLLING; CSMC EXTERNAL FACTORS AND OUTCOMES FOR HEART TRANSPLANT RECIPIENTS: A SINGLE CENTER SURVEY STUDY; JON KOBASHIGAWA, MD; ENROLLING; CSMC IMMUNOLOGIC RISK STUDY; EVAN KRANSDORF, MD; STUDY START-UP; INTERNAL OBSERVATIONAL REVIEW OF CLINICAL OUTCOMES IN HEART FAILURE PATIENTS UNDERGOING BARIATRIC SURGERY; MICHELE HAMILTON, MD; ENROLLING; CSMC A MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PHASE 3 STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL BPS-314D-MR ADDED-ON TO TREPROSTINIL, INHALED (TYVASO) IN SUBJECTS WITH PULMONARY ARTERIAL HYPERTENSION; ANTOINE HAGE, MD; CLOSED TO ENROLLMENT; LUNG BIOTECHNOLOGY, INC. A MULTICENTER, INTERNATIONAL, PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF DAILY ORAL DOSING OF TAFAMIDIS MEGLUMINE (PF-06291826) 20 MG OR 80 MG IN COMPARISON TO PLACEBO IN SUBJECTS DIAGNOSED WITH TRANSTHYRETIN CARDIOMYOPATHY (TTR-CM); JIGNESH PATEL, MD, PHD; ENROLLMENT COMPLETE; PFIZER A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF INHALED TREPROSTINIL IN SUBJECTS WITH PULMONARY HYPERTENSION DUE TO PARENCHYMAL LUNG DISEASE; ANTOINE HAGE, MD; ENROLLING; UNITED THERAPEUTICS A PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, EXTENSION STUDY TO EVALUATE THE SAFETY OF DAILY ORAL DOSING OF TAFAMIDIS MEGLUMINE 20MG OR 80MG IN SUBJECTS DIAGNOSED WITH TRANSTHYRETIN CARDIOMYOPATHY (TTR-CM); JIGNESH PATEL, MD, PHD; STUDY START-UP; PFIZER A PILOT RANDOMIZED STUDY TO ASSESS THE EFFECT AND SAFETY PROFILE OF THYMOGLOBULIN IN PRIMARY CARDIAC TRANSPLANT RECIPIENTS: A 12-MONTH, SINGLE CENTER, RANDOMIZED, OPEN-LABEL STUDY OF EFFICACY COMPARING IMMEDIATE TREATMENT WITH AND WITHOUT THYMOGLOBULIN 1.5 MG/KG/D FOR 5 CONSECUTIVE DAYS IN HEART TRANSPLANT RECIPIENTS; JON KOBASHIGAWA, MD; SCREENING; SANOFI A PROSPECTIVE, RANDOMIZED, CONTROLLED, UNBLINDED, MULTI-CENTER CLINICAL TRIAL TO EVALUATE THE HEARTWARE VENTRICULAR ASSIST DEVICE SYSTEM FOR DESTINATION THERAPY OF ADVANCED HEART FAILURE; JAIME MORIGUCHI, MD; ENROLLING; HEARTWARE, INC. A STUDY OF THE EFFICACY AND SAFETY OF BARDOXOLONE METHYL IN PATIENTS WITH CONNECTIVE TISSUE DISEASE-ASSOCIATED PULMONARY ARTERIAL HYPERTENSION; ANTOINE HAGE, MD; ENROLLING; REATA PHARMACEUTICALS, INC. AN OPEN-LABEL EXTENSION STUDY OF INHALED TREPROSTINIL IN SUBJECTS WITH PULMONARY HYPERTENSION DUE TO PARENCHYMAL LUNG DISEASE; ANTOINE HAGE, MD; ENROLLING; UNITED THERAPEUTICS AN OPEN-LABEL EXTENSION STUDY OF UT-15C IN SUBJECTS WITH PULMONARY ARTERIAL HYPERTENSION - A LONG-TERM FOLLOW-UP TO PROTOCOL TDE-PH-310; ANTOINE HAGE, MD; ENROLLING; UNITED THERAPEUTICS CARDIOMEMS HF SYSTEM POST APPROVAL STUDY; LAWRENCE CZER, MD; ENROLLING; ST. JUDE MEDICAL DREAM-HF - A DOUBLE-BLIND, RANDOMIZED, SHAM-PROCEDURE-CONTROLLED, PARALLEL-GROUP EFFICACY AND SAFETY STUDY OF ALLOGENEIC MESENCHYMAL PRECURSOR CELLS (CEP-41750) IN PATIENTS WITH CHRONIC HEART FAILURE DUE TO LEFT VENTRICULAR SYSTOLIC DYSFUNCTION OF EITHER ISCHEMIC OR NONISCHEMIC ETIOLOGY; DAVID CHANG, MD; ENROLLING; MESOBLAST, INC. GALACTIC HF STUDY - A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF OMECAMTIV MECARBIL ON MORTALITY AND MORBIDITY IN SUBJECTS WITH CHRONIC HEART FAILURE WITH REDUCED EJECTION FRACTION; DAVID CHANG, MD; ENROLLING; AMGEN OUTCOMES ALLOMAP REGISTRY (OAR) STUDY; JON KOBASHIGAWA, MD; ENROLLING; CAREDX, INC. PULMONARY HYPERTENSION POST-LEFT VENTRICULAR ASSIST DEVICE IMPLANTATION; JAIME MORIGUCHI, MD ENROLLING; ACTELION PHARMACEUTICALS RANGER - AN EXTENDED ACCESS PROGRAM TO ASSESS LONG-TERM SAFETY OF BARDOXOLONE METHYL IN PATIENTS WITH PULMONARY HYPERTENSION; ANTOINE HAGE, MD; ENROLLING; REATA PHARMACEUTICALS, INC. SERENADE - A MULTI-CENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2B STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MACITENTAN IN SUBJECTS WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION AND PULMONARY VASCULAR DISEASE; ANTOINE HAGE, MD; ENROLLING; ACTELION PHARMACEUTICALS SOUTHPAW - AN OPEN-LABEL EXTENSION STUDY OF ORAL TREPROSTINIL IN SUBJECTS WITH PULMONARY HYPERTENSION (PH) ASSOCIATED WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION (HFPEF) - A LONG-TERM FOLLOW-UP TO STUDY TDE-HF-301; ANTOINE HAGE, MD; ENROLLING; UNITED THERAPEUTICS STUDY TO EVALUATE THE EFFECT OF DAPAGLIFLOZIN ON THE INCIDENCE OF WORSENING HEART FAILURE OR CARDIOVASCULAR DEATH IN PATIENTS WITHCHRONIC HEART FAILURE WITH REDUCED EJECTION FRACTION; JIGNESH PATEL, MD, PHD; CLOSED TO ENROLLMENT; ASTRAZENECA US-BASED, OBSERVATIONAL, DRUG REGISTRY OF OPSUMIT (MACITENTAN) NEW USERS IN CLINICAL PRACTICE; ANTOINE HAGE, MD; ENROLLING; ACTELION PHARMACEUTICALS BIOMARKERS OF PRIMARY GRAFT DYSFUNCTION AFTER CARDIAC TRANSPLANTATION; JON KOBASHIGAWA, MD; ENROLLMENT COMPLETE; COLUMBIA UNIVERSITY CASH STUDY - CARDIAC SURGERY AFTER HEART TRANSPLANTATION - AN EXPLORATORY, RETROSPECTIVE, MULTICENTER STUDY; JON KOBASHIGAWA, MD; RETROSPECTIVE; MEDICAL UNIVERSITY OF VIENNA DIAGNOSTIC AND THERAPEUTIC APPLICATIONS OF MICROARRAYS IN HEART TRANSPLANTATION, A MULTICENTER STUDY; JON KOBASHIGAWA, MD; ENROLLING; UNIVERSITY OF ALBERTA ENTRESTOTM (LCZ696) IN ADVANCED HEART FAILURE (LIFE STUDY); EVAN KRANSDORF, MD; ENROLLING; DUKE UNIVERSITY INTERAGENCY REGISTRY FOR MECHANICALLY ASSISTED CIRCULATORY SUPPORT; DANNY RAMZY, MD, PHD; ENROLLING; UAB/NIH REGISTRY EVALUATION OF VITAL INFORMATION FOR VADS IN AMBULATORY LIFE; MICHELLE KITTLESON, MD, PHD; ENROLLMENT COMPLETE; UNIVERSITY OF MICHIGAN TRANSPLANT OF REDEEMED ORGANS BY JUDICIOUS ADMINISTRATION OF NEW DIRECT-ACTING ANTIVIRALS FOR HEPATITIS-C HEART RECIPIENTS (TROJAN-C); EVAN KRANSDORF, MD; STUDY START-UP; BAYLOR UNIVERSITY FORM 990, PART IV, LINE 12 THE ORGANIZATION WAS INCLUDED IN A CONSOLIDATED, INDEPENDENT AUDITED FINANCIAL STATEMENTS FOR THE FISCAL YEARS ENDED 6/30/17 AND 6/30/18 DUE TO THE FACT THAT THE TAX YEAR OF ITS TAX-EXEMPT PARENT ORGANIZATION, CEDARS-SINAI MEDICAL CENTER, ENDS ON 6/30. THERE ARE NO AUDITED FINANCIAL STATEMENTS FOR THE YEAR ENDED 12/31/17. FORM 990, PART VI, SECTION A, LINE 4 THE BY-LAWS OF THE ORGANIZATION WERE RESTATED DURING THE TAX YEAR, AND THE AUTHORIZED NUMBER OF DIRECTORS WERE REVISED TO BE NOT LESS THAN FIVE NOR MORE THAN NINE. FORM 990, PART VI, SECTION A, LINE 6 CEDARS-SINAI MEDICAL CENTER IS THE SOLE CORPORATE MEMBER OF CALIFORNIA HEART CENTER FOUNDATION. FORM 990, PART VI, SECTION A, LINE 7A CEDARS-SINAI MEDICAL CENTER AS THE SOLE CORPORATE MEMBER, CAN ELECT BOARD OF DIRECTORS TO CALIFORNIA HEART CENTER FOUNDATION. FORM 990, PART VI, SECTION A, LINE 7B RESERVED RIGHTS OF CEDARS-SINAI MEDICAL CENTER, THE SOLE CORPORATE MEMBER OF THE ORGANIZATION. THE FOLLOWING ACTIONS MUST BE APPROVED OR ACTED UPON BY CEDARS-SINAI MEDICAL CENTER BEFORE BECOMING EFFECTIVE: (A) ANY SALE OR OTHER DISPOSITION OF ALL OR A SUBSTANTIAL PORTION OF THE ASSETS OF THE ORGANIZATION; (B) ANY MERGER OR AFFILIATION OF THE ORGANIZATION WITH ANY PERSON OR ENTITY OTHER THAN THE MEMBER; (C) ANY AMENDMENT TO THE ARTICLES OF INCORPORATION OR BYLAWS OF THE ORGANIZATION; (D) ANY ACT OR OMISSION WHICH CREATES ANY MATERIAL RISK TO THE MEMBER'S TAX EXEMPT STATUS, OR CREATES ANY MATERIAL RISK OF A VIOLATION OF ANY STATE OR FEDERAL LAWS; (E) DISSOLUTION OF THE ORGANIZATION OR THE FILING OF ANY BANKRUPTCY PETITION; (F) CREATION OF ANY NEW CORPORATION, PARTNERSHIP OR ASSOCIATION; (G) ACQUISITION OF OR THE INVESTMENT IN A NEW OPERATING BUSINESS; (H) ENTERING INTO ANY PARTNERSHIPS OR JOINT VENTURES; (I) ADOPTION OF OR CHANGES TO OPERATING OR CAPITAL BUDGETS; (J) ADOPTION OF THIS CORPORATION'S POLICIES AND PROCEDURES; (K) EXECUTION AND DELIVERY OF ANY NEW AFFILIATION AGREEMENTS AND OTHER RELATIONSHIPS WITH THE UCLA SCHOOL OF MEDICINE AND OTHER INSTITUTIONS OF MEDICAL LEARNING; (L) UNBUDGETED CAPITAL EXPENDITURES OVER $100,000; (M) LOANS, BORROWINGS OR GUARANTEES IN EXCESS OF $100,000, UNLESS APPROVED IN THE BUDGET; (N) ANY SECURITY INTERESTS OR MORTGAGES ON THE PROPERTY OF ORGANIZATION; (O) OPERATING OR CAPITAL LEASES WHERE THE TERM IS OVER FIVE YEARS OR THE TOTAL OBLIGATION UNDER THE LEASE EXCEEDS $100,000, UNLESS APPROVED IN THE BUDGET; (P) TERMINATION OR SELECTION OF THE AUDITORS OF THE ORGANIZATION; (Q) APPOINTMENT OR REMOVAL OF ANY MEMBER OF THE BOARD (OTHER THAN EX-OFFICIO DIRECTORS); (R) APPOINTMENT OF REMOVAL OF ANY OFFICERS; (S) EXECUTION AND DELIVERY OF ANY PROFESSIONAL SERVICE AGREEMENTS; (T) RELOCATION OF PRINCIPAL OFFICE; AND (U) FIXING THE NUMBER OF DIRECTORS OF THE ORGANIZATION. FORM 990, PART VI, SECTION B, LINE 11B THE ORGANIZATION'S FORM 990 UNDERGOES AN INTENSE AND HIGHLY COMPREHENSIVE REVIEW PROCESS. THE REVIEW INVOLVES VARIOUS MANAGEMENT PERSONNEL AND A BIG FOUR ACCOUNTING FIRM. FORM 990, PART VI, SECTION B, LINE 12C CONFLICT OF INTEREST POLICY ANNUAL STATEMENTS: EACH DIRECTOR, OFFICER, MEMBER OF A COMMITTEE WITH BOARD-DELEGATED POWERS AND ANY OTHER INTERESTED PERSON AS DETERMINED BY THE BOARD OR COMMITTEE SHALL AT LEAST ANNUALLY SIGN A COPY OF THE "STATEMENT PERTAINING TO CONFLICT OF INTEREST." IF A DIRECTOR, OFFICER, OR COMMITTEE MEMBER, OR DESIGNATED INTERESTED PERSON BECOMES AWARE THAT A POTENTIAL OR APPARENT CONFLICT MAY EXIST WHICH IS NOT DISCLOSED ON SUCH A STATEMENT, IT SHALL BE THE RESPONSIBILITY OF THE INTERESTED PERSON TO DISCLOSE THE POTENTIAL CONFLICT TO THE PRESIDENT AND TO THE BOARD OR APPROPRIATE COMMITTEE AND AS SET FORTH ABOVE, PRIOR TO ANY BOARD OR COMMITTEE DISCUSSIONS OR ACTION WITH RESPECT TO THE RELEVANT TRANSACTION OR ARRANGEMENT, AND, IF RELEVANT, TO LEAVE THE MEETING DURING THE DISCUSSION AND VOTE ON THE TRANSACTION OR ARRANGEMENT. DETERMINING WHETHER A CONFLICT OF INTEREST EXISTS: IF CONSIDERATION OF THE TRANSACTION OR ARRANGEMENT AT ISSUE IS A MATTER WITHIN THE SCOPE OF AUTHORITY OF THE BOARD OF DIRECTORS OR A COMMITTEE, AFTER DISCLOSURE OF THE FINANCIAL INTEREST AND AFTER ANY DISCUSSION WITH THE INTERESTED PERSON, THE RELEVANT CALIFORNIA HEART CENTER FOUNDATION ("CHCF") OFFICER OR ADMINISTRATOR SHALL DETERMINE WHETHER A CONFLICT OF INTEREST EXISTS. IF IT IS DETERMINED THAT A CONFLICT OF INTEREST EXISTS AND, NOTWITHSTANDING THE CONFLICT, THE CHCF OFFICER OR ADMINISTRATOR DETERMINES THAT IT CONTINUES TO BE IN THE BEST INTERESTS OF CHCF TO PROCEED WITH THE TRANSACTION OR ARRANGEMENT AT ISSUE, THE CHCF OFFICER OR ADMINISTRATOR SHALL REFER THE TRANSACTION OR ARRANGEMENT TO THE BOARD OR THE APPROPRIATE BOARD-DESIGNATED COMMITTEE FOR EVALUATION. ALTERNATIVELY IF CONSIDERATION OF THE TRANSACTION OR ARRANGEMENT AT ISSUE IS A MATTER WITHIN THE SCOPE OF THE AUTHORITY OF THE BOARD OF DIRECTORS OR A COMMITTEE, THE INTERESTED PERSON SHALL LEAVE THE BOARD OR COMMITTEE MEETING WHILE THE DETERMINATION OF THE EXISTENCE OF A CONFLICT OF INTEREST IS DISCUSSED AND VOTED UPON. THE REMAINING BOARD OR COMMITTEE MEMBERS SHALL DECIDE, BY MAJORITY VOTE, IF A CONFLICT OF INTEREST EXISTS. PROCEDURES FOR ADDRESSING THE CONFLICT OF INTEREST: A. AN INTERESTED PERSON MAY MAKE A PRESENTATION TO THE BOARD OR COMMITTEE REGARDING THE TRANSACTION OR ARRANGEMENT. AFTER SUCH PRESENTATION THE INTERESTED PERSON MUST LEAVE THE MEETING DURING THE DISCUSSION OF, AND THE VOTE ON THE TRANSACTION OR ARRANGEMENT. B. THE CHAIR OF THE BOARD OR COMMITTEE SHALL, IF DEEMED APPROPRIATE BY THE BOARD OR COMMITTEE, APPOINT A DISINTERESTED PERSON OR COMMITTEE TO INVESTIGATE ALTERNATIVES TO THE PROPOSED TRANSACTION OR ARRANGEMENT. C. AFTER EXERCISING DUE DILIGENCE, THE BOARD OR COMMITTEE SHALL DETERMINE WHETHER CHCF CAN OBTAIN A MORE ADVANTAGEOUS TRANSACTION OR ARRANGEMENT WITH REASONABLE EFFORTS FROM A PERSON OR ENTITY THAT WOULD NOT GIVE RISE TO A CONFLICT OF INTEREST. D. IF A MORE ADVANTAGEOUS TRANSACTION OR ARRANGEMENT IS NOT REASONABLY ATTAINABLE UNDER CIRCUMSTANCES THAT WOULD NOT GIVE RISE TO A CONFLICT OF INTEREST, THE BOARD OR COMMITTEE SHALL DETERMINE BY A MAJORITY VOTE OF THE DISINTERESTED DIRECTORS WHETHER THE TRANSACTION OR ARRANGEMENT IS IN CHCF' BEST INTEREST AND FOR ITS OWN BENEFIT AND WHETHER THE TRANSACTION IS FAIR AND REASONABLE TO CHCF AND SHALL MAKE ITS DECISION AS TO WHETHER TO ENTER INTO THE TRANSACTION OR ARRANGEMENT IN CONFORMITY WITH SUCH DETERMINATION. VIOLATIONS OF THE CONFLICTS POLICY: A. IF THE BOARD OR COMMITTEE HAS REASONABLE CAUSE TO BELIEVE THAT A MEMBER OF THE BOARD OR COMMITTEE OR AN OFFICER OR OTHER INTERESTED PERSON HAS FAILED TO DISCLOSE AN ACTUAL OR POSSIBLE CONFLICT OF INTEREST, IT SHALL INFORM THE MEMBER OR OFFICER OR INTERESTED PERSON OF THE BASIS FOR SUCH BELIEF AND AFFORD SUCH PERSON AN OPPORTUNITY TO EXPLAIN THE ALLEGED FAILURE TO DISCLOSE. B. IF, AFTER HEARING THE RESPONSE OF SUCH PERSON AND MAKING SUCH FURTHER INVESTIGATION AS MAY BE WARRANTED IN THE CIRCUMSTANCES, THE BOARD OR COMMITTEE DETERMINES THAT SUCH PERSON HAS IN FACT FAILED TO DISCLOSE AN ACTUAL OR POSSIBLE CONFLICT OF INTEREST, IT SHALL TAKE APPROPRIATE DISCIPLINARY AND CORRECTIVE ACTION. FORM 990, PART VI, SECTION B, LINE 15B THE EXECUTIVE PERSONNEL COMMITTEE (THE COMMITTEE) OF THE TAX-EXEMPT PARENT OF THE ORGANIZATION, CEDARS-SINAI MEDICAL CENTER, IS A STANDING COMMITTEE OF THE BOARD OF DIRECTORS. THE COMMITTEE ADDRESSES COMPENSATION AND BENEFITS REGARDING THE ORGANIZATION'S CHIEF FINANCIAL OFFICER AND BOARD MEMBERS WHO ARE ALSO EXECUTIVE EMPLOYEES AND CONTRACTUALLY ENGAGED FACULTY OF THE MEDICAL CENTER, AND IS AUTHORIZED BY THE BOARD OF DIRECTORS TO ACT ON BEHALF OF THE BOARD WITH RESPECT TO SUCH ISSUES, AND OTHER GOVERNANCE ISSUES AS REQUESTED BY THE BOARD OF DIRECTORS, THE EXECUTIVE COMMITTEE OF THE BOARD OF DIRECTORS, THE CHAIR OF THE BOARD OF DIRECTORS, OR THE CEO, ALL SUBJECT TO THE COMMITTEE'S ONGOING REPORTING OBLIGATION TO THE BOARD OF DIRECTORS OR THE EXECUTIVE COMMITTEE OF THE BOARD OF DIRECTORS. SPECIFICALLY, THE COMMITTEE EVALUATES THE PERFORMANCE AND APPROVES THE COMPENSATION AND BENEFITS FOR THE ORGANIZATION'S CHIEF FINANCIAL OFFICER AND BOARD MEMBERS WHO ARE ALSO EXECUTIVE EMPLOYEES AND CONTRACTUALLY ENGAGED FACULTY OF THE MEDICAL CENTER. THE MEMBERS OF THE COMMITTEE ARE APPOINTED ANNUALLY BY THE CHAIR OF THE MEDICAL CENTER'S BOARD OF DIRECTORS. APPOINTMENTS ARE FOR A ONE YEAR TERM. EACH YEAR, THE COMMITTEE FOLLOWS A PROCESS THAT ENSURES THAT THE COMPENSATION AND BENEFITS IS REASONABLE AND IN COMPLIANCE WITH APPLICABLE LAWS AND REGULATIONS. THE MEDICAL CENTER'S SVP OF HR PROVIDES STAFF SUPPORT TO THE COMMITTEE. THE COMMITTEE MAY INCLUDE MEMBERS OF THE MEDICAL CENTER'S MANAGEMENT TEAM OR ANY OTHER PERSON WHOSE PRESENCE THE COMMITTEE BELIEVES TO BE DESIRABLE OR APPROPRIATE. THE COMMITTEE MAY ENGAGE AN INDEPENDENT COMPENSATION AND BENEFITS CONSULTANT AND ANY OTHER ADVISORS THEY DEEM NECESSARY. THE COMMITTEE MAY ALSO ENGAGE INDEPENDENT COUNSEL. THE MEDICAL CENTER WILL PROVIDE FOR APPROPRIATE FUNDING FOR PAYMENT OF COSTS TO ANY SUCH PERSONS RETAINED BY THE COMMITTEE. ANNUALLY, AT THE COMMITTEE'S DIRECTION, THE INDEPENDENT COMPENSATION CONSULTANT SHALL PREPARE SUCH REPORTS AS THE COMMITTEE REASONABLY DEEMS NECESSARY. AT A MINIMUM, SUCH REPORTS WILL INCLUDE MARKET SURVEY DATA FROM A PEER GROUP DESIGNATED BY THE COMMITTEE, WHICH SHALL BE CONSIDERED BY THE COMMITTEE PRIOR TO MAKING DECISIONS. THE COMMITTEE MEETS AS FREQUENTLY AS THE COMMITTEE DEEMS NECESSARY AND WILL MAINTAIN WRITTEN MINUTES OF ITS MEETING. THE COMPENSATION AND BENEFITS OF THE PRESIDENT AND VICE-PRESIDENT ARE DETERMINED BY THE CHIEF FINANCIAL OFFICER OF THE ORGANIZATION WITH ASSISTANCE FROM HR WHICH PROVIDES AN INDEPENDENT REVIEW OF COMPARABLES. FORM 990, PART VI, SECTION C, LINE 19 THE ORGANIZATION MAKES ITS GOVERNING DOCUMENTS, ITS CONFLICT OF INTEREST POLICY AND ITS TAX-EXEMPT PARENT'S AUDITED FINANCIAL STATEMENTS AVAILABLE TO THE PUBLIC UPON WRITTEN REQUEST. FORM 990, PART XI, LINE 9: ROUNDING 1. CEDARS-SINAI MEDICAL CENTER 8700 BEVERLY BOULEVARD LOS ANGELES CA 90048 951644600 HEALTHCARE CA 501(C)(3) LINE 3 CEDARS-SINAI HEALTH SYSTEM 0 CEDARS-SINAI MEDICAL CARE FOUNDATION 200 N ROBERTSON BOULEVARD 101 BEVERLY HILLS CA 90211 954457756 PROVISION OF MEDICAL CARE, TEACHING AND RESEARCH CA 501(C)(3) LINE 12A, I CEDARS-SINAI MEDICAL CENTER 1 KERLAN-JOBE ORTHOPAEDIC FOUNDATION 6801 PARK TERRACE LOS ANGELES CA 90045 954707606 EDUCATION AND RESEARCH RELATED TO ORTHOPAEDIC MEDICINE CA 501(C)(3) LINE 7 CEDARS-SINAI MEDICAL CARE FOUNDATION 1 SANTA MONICA ORTHOPAEDIC & SPORTS MED RESEARCH FDN 2020 SANTA MONICA BLVD 4TH FLR SANTA MONICA CA 90404 954789926 EDUCATION AND RESEARCH RELATED TO ORTHOPAEDIC AND NEUROLOGIC CONDITIONS CA 501(C)(3) PF CEDARS-SINAI MEDICAL CARE FOUNDATION 1 CFHS HOLDINGS INC 4650 LINCOLN BLVD MARINA DEL REY CA 90292 201645949 HEALTHCARE CA 501(C)(3) LINE 3 CEDARS-SINAI MEDICAL CENTER 1 CEDARS-SINAI HEALTH SYSTEM 8700 BEVERLY BOULEVARD LOS ANGELES CA 90048 300990905 SUPPORT SPECIFIED NONPROFIT HEALTHCARE ORGANIZATIONS CA 501(C)(3) LINE 12C, III-FI N/A 0 ENDOSCOPY CENTER OF SANTA MONICA LLC 12400 WILSHIRE BLVD STE 100 LOS ANGELES CA 90025 113652210 ENDOSCOPIES AND RELATED PROCEDURES CA N/A ISS ASC HOLDINGS LLC 27271 LAS RAMBLAS STE 350 MISSION VIEJO CA 92691 471890805 INVESTMENT IN HEALTHCARE SERVICES CA N/A DEL REY SURGERY INVESTORS LLC 11150 SANTA MONICA BLVD STE 700 LOS ANGELES CA 90025 364756208 INVESTMENT IN AMBULATORY SURGERY CENTER DE N/A DEL REY SURGERY CENTER LLC 27271 LAS RAMBLAS STE 350 MISSION VIEJO CA 92691 462305372 OPERATOR OF AMBULATORY SURGERY CENTER CA N/A CEDARS-SINAI BH ASC LLC 200 N ROBERTSON BLVD 101 BEVERLY HILLS CA 90211 812266744 HOLDING COMPANY CA N/A CS-BH ASC HOLDINGS LLC 200 N ROBERTSON BLVD 101 BEVERLY HILLS CA 90211 812246488 HOLDING COMPANY CA N/A INTERNATIONAL SPINE & ORTHOPEDIC INSTITUTE LLC 8500 W 110TH ST OVERLAND PARK KS 66210 263738893 SPINE AND ORTHOPEDIC INSTITUTE DE N/A SANTA MONICA IMAGING GROUP LLC 200 N ROBERTSON BLVD 101 BEVERLY HILLS CA 90211 820760657 IMAGING CENTER CA N/A OPTIMATRIX HEALTH SOLUTIONS INC 6500 WILSHIRE BLVD 9TH FLR LOS ANGELES CA 90048 954522779 INFORMATION SYSTEMS CA N/A C 1 CENTINELA FREEMAN HOLDINGS INC 4650 LINCOLN BLVD MARINA DEL REY CA 90292 593811890 MEDICAL OFFICE BUILDING AND GROUND LEASE LESSOR CA N/A C 1 OTOHARMONICS CORPORATION 411 SW 6TH AVE PORTLAND OR 97204 461119421 HEALTHCARE PRODUCT DEVELOPMENT DE N/A C 1 0 0 1 0 0 0 0 0 0 0 0 0 0 1 1 1 0 0 0